Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis assessed by visual analogue scale and endoscopy

摘要

IntroductionMost allergic rhinitis (AR) patients have moderate‐to‐severe, persistent disease. Meda Pharma's AzeFlu (MP‐AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterventional study sought to assess the effectiveness of MP‐AzeFlu (one sprayostril twice daily; 548 µg AZE/200 µg FP daily dose) in relieving AR symptom severity.